Related Experiment Videos
Increased serum levels of vascular endothelial growth factor in human crescentic glomerulonephritis
1Department of Medicine, Kidney Center, Tokyo Women's Medical University, Japan.
Insights
Serum vascular endothelial growth factor (VEGF) is elevated in crescentic glomerulonephritis (CRGN) and correlates with disease severity. Corticosteroid therapy may reduce VEGF levels in CRGN patients.
Area of Science:
- Nephrology
- Immunology
- Pathology
Background:
- Crescentic glomerulonephritis (CRGN) is a severe kidney disease characterized by rapid glomerular damage.
- Vascular Endothelial Growth Factor (VEGF) plays a crucial role in angiogenesis and vascular permeability, potentially contributing to kidney injury.
Purpose of the Study:
- To investigate serum VEGF levels in patients with human crescentic glomerulonephritis (CRGN).
- To compare VEGF levels in CRGN patients with healthy controls and other glomerulonephritis types.
- To explore the relationship between serum VEGF, creatinine, and pathological parameters in CRGN.
Main Methods:
- Serum VEGF levels were measured in CRGN patients, healthy subjects, and patients with other glomerulonephritis types (MCNS, IgAN, FGS).
- Correlation analysis was performed between serum VEGF levels, serum creatinine (Scr), and pathological parameters (crescent frequency, interstitial injury, macrophage infiltration).
- VEGF levels were monitored before and after corticosteroid therapy in a subset of CRGN patients.
Main Results:
- Serum VEGF levels were significantly higher in CRGN patients compared to healthy subjects and patients with MCNS, IgAN, and FGS.
- Serum VEGF levels correlated significantly with crescent frequency, interstitial injury grade, and macrophage infiltration in CRGN kidneys.
- Serum VEGF levels decreased significantly after 6 months of corticosteroid therapy in CRGN patients.
- No correlation was found between serum VEGF and Scr in rapidly progressive glomerulonephritis (RPGN) patients.
Conclusions:
- Elevated serum VEGF levels in CRGN patients are associated with severe glomerular and interstitial damage.
- Corticosteroid therapy may improve CRGN outcomes, potentially by reducing serum VEGF levels.
- VEGF may serve as a biomarker for disease activity and therapeutic response in crescentic glomerulonephritis.
Objective:
To investigate the serum levels of vascular endothelial growth factor (VEGF) in human crescentic glomerulonephritis (CRGN).
Methods:
The serum VEGF levels in CRGN patients were compared with those in healthy subjects and in various types of glomerulonephritis. In addition, we investigated the relationship between serum VEGF levels and creatinine levels (Scr) and pathological parameters.
Results:
The serum VEGF levels of the CRGN patients were significantly higher than in the healthy subjects and patients with MCNS, IgAN, and FGS. No correlation was found between serum VEGF levels and Scr in the RPGN patients. The serum VEGF levels in 6 CRGN patients had significantly decreased after 6 months of corticosteroid therapy. Moreover, there was a significant correlation between the serum VEGF levels and the crescent frequency or the grade of interstitial injury, and the rates of glomerular infiltration by macrophages.
Conclusions:
In the CRGN patients, severe glomerular and interstitial damages would result in increased serum VEGF levels and corticosteroid therapy may exert its efficacy through reduction of serum VEGF levels.